Keyphrases
Malignant Disorders
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Graft-versus-host Disease (GvHD)
100%
Alloreactive
50%
Graft-versus-leukemia Effect
50%
Immune Response
25%
Monoclonal Antibody
25%
Dissociation
25%
Malignancy
25%
Therapeutic Modalities
25%
T Cells
25%
T Cell Receptor
25%
Genetic Modification
25%
Antitumor
25%
Patients with Hematological Malignancies
25%
Malignant Cells
25%
Tumor Antigen
25%
Tumor-specific
25%
Leukemia-associated Antigen
25%
Natural Killer Cells
25%
Therapeutic Efficacy
25%
Chimeric Antigen Receptor T Cells (CAR-T)
25%
Tumor Targeting
25%
Bispecific
25%
Tumor Immunity
25%
Targeted Immunotherapy
25%
Immune Effectors
25%
Antigen Targeting
25%
Engager
25%
Hematopoietic Tissue
25%
Donor Lymphocytes
25%
GVL Effect
25%
Minor Histocompatibility Antigens
25%
Natural Killer Cell Immunotherapy
25%
Reaction Attack
25%
Medicine and Dentistry
Disease
100%
Immunotherapy
100%
Allogeneic Hematopoietic Stem Cell Transplantation
100%
Graft Versus Host Reaction
100%
Neoplasm
50%
Natural Killer Cell
50%
Epileptic Absence
25%
Lymphocyte
25%
Therapeutic Modality
25%
Combination Therapy
25%
T Lymphocyte Receptor
25%
Hematologic Malignancy
25%
Monoclonal Antibody
25%
Cancer
25%
Tumor Antigen
25%
T Cell
25%
Immune Response
25%
Tumor Immunity
25%
Graft Versus Leukemia Effect
25%
Graft Versus Tumor Effect
25%
Chimeric Antigen Receptor
25%
Hematopoietic Tissue
25%
Minor Histocompatibility Antigen
25%
Leukemia Antigen
25%
Immunology and Microbiology
Graft-Versus-Host Disease
100%
Immunotherapy
100%
Allogeneic Hematopoietic Stem Cell Transplantation
100%
Natural Killer Cell
50%
Monoclonal Antibody
25%
Lymphocyte
25%
T Cell
25%
T Cell Receptor
25%
Immune Response
25%
Tumor Antigen
25%
Tumor Immunity
25%
Hematopoietic Tissue
25%
Graft Versus Tumor Effect
25%
Chimeric Antigen Receptor
25%
Minor Histocompatibility Antigen
25%
Leukemia Antigen
25%